替格瑞洛作為一種新型抗血小板藥物，常與阿司匹林聯(lián)用治療急性冠脈綜合征或有心肌梗死病史且伴有至少一種動(dòng)脈粥樣硬化血栓形成事件高危因素的患者，但對(duì)于亞洲人群可伴隨更高的出血風(fēng)險(xiǎn)，為此越來(lái)越多的研究聚焦于低劑量替格瑞洛的療效和安全性。系統(tǒng)檢索了國(guó)內(nèi)外有關(guān)低劑量替格瑞洛聯(lián)合阿司匹林在冠心病患者中的臨床應(yīng)用，對(duì)文獻(xiàn)進(jìn)行整理，從對(duì)血小板功能的影響，治療急性冠脈綜合征、穩(wěn)定型冠心病的效果以及藥物安全性的角度，對(duì)不同治療方案的臨床效果進(jìn)行評(píng)價(jià)，并對(duì)當(dāng)前正在進(jìn)行的研究以及未來(lái)的研究方向進(jìn)行展望。

As a new type of antiplatelet drug, ticagrelor is often used in combination with aspirin to treat patients with acute coronary syndrome or a history of myocardial infarction accompanied by at least one high-risk factor for atherosclerotic thrombosis events. But for Asian populations, ticagrelor displayed a higher risk of bleeding. For this reason, more and more studies have focused on the efficacy and safety of low-dose ticagrelor. This review systematically searched the clinical studies of low-dose ticagrelor combined with aspirin in patients with coronary heart disease. We reviewed these literatures, and evaluated the clinical effects of different therapeutic regimens. From the aspects of the effect on platelet function, the effect of treating acute coronary syndrome and stable coronary heart disease, and drug safety, the current ongoing research and future research directions were looked forward.<

R972

天津市醫(yī)院協(xié)會(huì)醫(yī)院管理研究項(xiàng)目（20192203）